Disruption of the secretion of insulin-like growth factor 2 for cancer treatment
AssigneeThe Hong Kong University of Science and Technology
InventorsYusong GUO, Tiantian LI
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Hong Kong University of Science and Technology
InventorsYusong GUO, Tiantian LI
Estimating the term…
The subject invention pertains to compositions and methods for inhibiting IGF2 signaling. Insulin-like growth factor 2 (IGF2) is a key signaling molecule that plays important roles in various physiological processes, including skeletal myogenesis during development and adult muscle remodeling. Abnormal activation of the signaling pathway induced by IGF2 has been shown to promote cancer progression. TMED10, a p24 family protein, functions as a cargo receptor, promoting the export of IGF2 from the endoplasmic reticulum (ER) via recognizing an ER export signal on IGF2. Moreover, TMED10 also mediates ER export of sortilin, which is important to regulate the export of IGF2 from the trans-Golgi network. The subject invention features a novel therapeutic strategy for cancer treatment, that includes, but is not limited to, inhibitors targeting the interaction between IGF2 and TMED10.
A pharmaceutical composition for inhibiting IGF2 signaling, the composition comprising an inhibitor of IGF2-TMED10 interaction in a cell and one or more pharmaceutical carriers or excipients.
A method of treating a subject having abnormal IGF2 signaling, the method comprising:
A method of treating cancer in a subject in need thereof, the method comprising:
Dependencies are inferred from the claim text.